

NTProBNP AND HRV AND OUTCOME IN PATIENTS WITH HEART FAILURE WITH REDUCED VS. PRESERVED SYSTOLIC FUNCTION

Nadya Stancheva¹, Snezhana Tisheva¹, Virginia Jordanova¹, Stanimir Kurkchiev², Assen Goudev³

1) Clinic of Cardiology and Rheumatology, UMHAT "G. Stranski" - Pleven;

2) Institute of Biology and Immunology of Reproduction, Bulgarian Academy of Science - Sofia;

3) Clinic of Cardiology with Intensive care Unit, UMHAT "Tsaritsa Ioanna" – Sofia, Bulgaria.

ABSTRACT:

Background : Heart failure /HF/ is usually associated with reduced systolic function. Elevated plasma concentrations of NTproBNP and heart rate variability /HRV/ are predictive of worse outcome in HF patients but there are few data about its predictive value in patients with HF and preserved systolic function.

Purpose and methods: The aim of this study was to determine the prognostic value of predischage NT-proBNP and heart rate variability (HRV) in patients with reduced vs. preserved systolic function admitted for decompensated congestive HF. One hundred and twenty-seven patients were evaluated at the time of discharge by means of echocardiography, conventional laboratory tests, plasma for NTproBNP and Holter ECG for HRV. The primary endpoints of the study were defined as readmission for HF during the first 6 months after discharge, more than 2 hospitalizations for 1 year, or cardiac death.

Results: One hundred and twenty-one patients /95.3%/ were followed for mean of 387 ± 117 days. Fifty-four patients /44.6%/ had reduced systolic function. Despite of the significant differences in the clinical characteristics of the patients with HF with reduced vs preserved systolic function, prognosis in both groups was poor. Predischage NTproBNP levels were predictive of worse outcome irrespectively of the systolic function. Kaplan-Meier survival curves showed that NTproBNP > 300 pg/ml was associated with significantly worse outcome in both groups and HRV < 20 ms was predictive of event occurrence in the reduced systolic function group. HRV reflected the severity of the systolic dysfunction in the reduced systolic function group.

Conclusions: In hospitalized HF patients predischage NTproBNP levels are associated with poor prognosis in HF patients irrespectively of systolic function while HRV reflects the severity and poor prognosis only of heart failure with reduced systolic function.

Key words: brain natriuretic peptide, heart rate variability, heart failure, prognosis

INTRODUCTION.

Heart failure /HF/ is usually the most frequent reason for morbidity, mortality and frequent rehospitalizations. [1-3] In order to optimize the healthcare for chronically ill patients researchers continuously search for new non-invasive methods of predicting the risk. The relationship between poor prognosis in chronic HF and neurohormones has already been established. [4-9] Neurohumoral activation is predictive of fatal and non-fatal cardiovascular events in patients with chronic HF. [10] A lot of authors confirm the role of brain natriuretic peptide /NTproBNP/ as a biochemical marker with high sensitivity and moderate specificity. Heart rate variability /HRV/ in HF is mainly predictive of the risk for cardiac death and pump failure. [11-14] Most studies on the prognostic value of HRV comprise patients with old myocardial infarction or ischemic heart disease with the presumption that the impaired autonomic control of cardiovascular system is one of the mechanisms of cardiac death, especially sudden cardiac death. [15-17] It is only recently that researchers have directed their efforts to establish the role of HRV in chronic HF. Usually HF is identified with systolic dysfunction and little is known about the prognosis of HF with preserved systolic function /HFPSF/. The aim of this study was to determine the prognostic value of predischage NT-proBNP and HRV in patients with reduced vs. preserved systolic function HF.

MATERIAL AND METHODS.

This study was approved by the local ethic committee of the Medical University of Pleven.

One hundred and twenty-seven patients who fulfilled the Framingham criteria for heart failure and were hospitalized in the Clinic of Cardiology and Rheumatology in the University Hospital 'Dr Georgi Stranski' in Pleven, Bulgaria

participated in the study. All patients underwent chest X-ray, two-dimensional echocardiography, standard 12-lead ECG, and blood samples were taken for predischARGE levels of NTproBNP, haemoglobin and creatinine. NTproBNP measurement was performed by means of immunoenzyme quantitative ELISA kit of Biomedica Gruppe in the Institute of Biology and Immunology of Reproduction, Bulgarian Academy of Science - Sofia. HRV was evaluated by means of 24-hour Holter ECG in 46 of the patients /38.0%/ in the day of discharge \pm 1 day with Cardiotsens machine. Patients with no sinus rhythm were excluded from the analysis of HRV. The ECG readings were manually inspected, and all the intervals containing artifacts and ectopic beats were excluded being replaced by the preceding normal RR intervals. All time HRV indices were measured and calculated automatically. Patients were divided into two groups – I group of patients with HF and reduced systolic function /HFRSF/ defined as ejection fraction /EF/ < 40% and group II of the patients with heart failure and preserved systolic function /HFPSF/ defined as EF \geq 40%. The primary endpoints of the study were defined as readmission for HF during the first 6 months after discharge, more than 2 hospitalizations for 1 year, or cardiac death.

RESULTS.

One hundred and twenty-one of the patients /95.3%/ were followed for mean of 387 ± 117 days. Of them 54 patients /65.3%/ had reduced systolic function. The main quantitative and qualitative characteristics of both groups are shown in tables 1 and 2 respectively.

The minimal predischARGE value of NTproBNP in patients with HFRSF was 61,695 pg/ml, the maximal was 1951,49 pg/ml. The median value of NTproBNP was 249.839 pg/ml. By means of non-parametric percentile method 3 groups were formed according to the plasma levels of NTproBNP, presented in table 3. There was significant difference in the concentration of NTproBNP /respectively 283.4 and 123.7, Kruskal-Wallis test = 11.28, $p < 0.001$ / in the event and non-event group, figure 1. There was also significant difference between the median value of NTproBNP of those who died and those who survived /respectively 573.4 versus 202.8, Kruskal-Wallis test = 11.35, $p < 0.001$ /. Patients who were rehospitalized within 6 months of discharge had significantly higher plasma concentration of NTproBNP than those who were not /respectively 331.8 versus 167.8, Kruskal-Wallis test = 11.62, $p < 0.001$ /. Similar result was obtained when comparing the group of patients with more than 2 heart failure hospitalizations for one year and those who were not hospitalized /NTproBNP respectively 329.6 versus 146.0, Kruskal-Wallis test = 16.15, $p < 0.001$ /.

The minimal predischARGE value of NTproBNP in patients with HFPSF was 19.313 pg/ml, the maximal was 1615.18 pg/ml. The median value of NTproBNP was 124.935 pg/ml. By means of non-parametric percentile method 3

groups were formed according to the plasma levels of NTproBNP, presented in table 4. There was significant difference between the concentration of NTproBNP /respectively 168.5 versus 120.0, Kruskal-Wallis test = 9.55, $p < 0.01$ / in the event and non-event group, figure 2. There was also significant difference between the median value of NTproBNP of those who died and those who survived /respectively 333.8 versus 123.1, Kruskal-Wallis test = 6.58, $p = 0.01$ /. Between patients who were rehospitalized within 6 months of discharge and those who were not there was not statistical difference in the plasma concentration of NTproBNP /respectively 150.3 versus 124.2 pg/ml, Kruskal-Wallis test = 1.30, $p = 0.25$ /. At the same time when comparing the group of patients with more than 2 heart failure hospitalizations for one year and those who were not hospitalized there was statistical difference in NTproBNP plasma concentration /respectively 224.9 versus 121.0 pg/ml, Kruskal-Wallis test = 10.26, $p < 0.01$ /.

Kaplan-Meier event-free survival curves in the three groups according to NTproBNP plasma concentration in HFRSF and HFPSF are shown on figure 3 and figure 4. There was significant difference in the survival rate in the three NTproBNP subgroups both in HFRSF and HFPSF.

When comparing the different HRV indices in HFRSF and HFPSF it was evident that there was no relationship between SDNN and systolic function /respectively 91 ms in HFRSF and 99 ms in HFPSF, Kruskal-Wallis test = 0.5, $p = 0.5$ /. There was statistically significant difference between the time HRV indices SDNN, SDANN, SDNNindex, HRVti and TINN in the HFRSF group, table 5. There was no significant difference between the median value of SDNN in the group of the non-survivals versus the survivals /respectively 63 versus 91 ms, Kruskal-Wallis test = 1.89, $p = 0.17$ /. There was not statistical difference in both time and frequency HRV indices between patients with HFRSF who were rehospitalized within 6 months after discharge and those who were not. At the same time patients who were hospitalized at least twice for a period of one year had significantly lower HRV as compared to those who were not hospitalized /SDNN respectively 63 versus 91 ms, Kruskal-Wallis test = 3.63, $p < 0.05$ /. In HFPSF patients there was no difference in any of the HRV indices between the event and event-free group and between the rehospitalized patients within 6 months after discharge and those who were not hospitalized. The same result was obtained when comparing the non-survival and survival group /SDNN respectively 75 versus 106 ms, Kruskal-Wallis test = 1.57, $p = 0.2$ /, but as one can see there was a tendency of lower HRV in the non-survival group. When comparing the group of HFPSF patients with more than 2 heart failure hospitalizations for one year and those who were not hospitalized there was not statistical difference in HRV values /SDNN respectively 67 versus 110 ms, Kruskal-Wallis test = 1.7, $p = 0.2$ /. Kaplan-Meier event-free survival curves for patients with HFRSF showed worse survival rate

with lower HRV /HRVti<20/, figure 5. There was no significant difference in the survival rate of patients with HFPSF dependent on HRV indices.

DISCUSSION.

Patients with HF and preserved systolic function represent a distinct group of patients with their typical characteristics. These are patients who very often do not fall among the randomized patients in big clinical trials as patients with reduced systolic function do. As a result of this there is very small amount of scientific data concerning the characteristics, treatment and prognosis of this group of patients. Furthermore, it turns out that these patients differ in their clinical presentations from the patients with HFRSF. In our study we put emphasis not only on the clinical characteristics but even more on the prognostic importance of neurohumoral activation presented by NTproBNP and heart rate variability in patients with HFPSF as compared to HFRSF. The endpoint of cardiac death cannot be trustfully evaluated in this small study with a very low rate of death cases occurred. What results really show is that in both groups the frequency of primary endpoints is very high. Outcome in patients with HFPSF seems to be more favorable but 19.4% of the patients with HFPSF were hospitalized at least twice for a period of 1 year, and nearly 12% of them

were rehospitalized within 6 months after discharge.

CONCLUSIONS.

1. Despite the significant differences in the clinical characteristics of the patients with HFRSF and HFPSF prognosis in both groups is poor.

2. PredischARGE plasma concentration of NTproBNP is an independent prognostic marker both in HFRSF and HFPSF. Kaplan-Meier NTproBNP dependent survival curves show that both in HFRSH and HFPSH predischARGE NTproBNP levels greater than 300pg/ml are connected with a significantly lower rate of survival.

3. Heart rate variability reflects to a certain degree the severity of HFRSF. Heart rate variability is an independent prognostic marker in HFRSF, but not in HFPSF.

Limitations of the study.

Only 121 patients took part in the study, but the percentage of reached at least one endpoint was high /45 %/. The population consisted of mainly young patients with high incidence of diabetes mellitus and arterial hypertension, which fact necessitates validation of the results in a big prospective study. The impact of therapy on NTproBNP and HRV has not been taken into account due to financial reasons and this will be object of further investigations.

Table 1. Comparison of main qualitative characteristics according to systolic function.

Characteristics	HFRSF/n=54/		HFPSF/n=67/		Comparison	
	n	%	n	%	Student's t criterion	p value
Male	42	77.8	27	40.3	4.88	p < 0.001
Diabetes mellitus type 2	18	33.3	19	28.4	0.32	NS
Arterial hypertension	41	75.9	59	88.1	1.77	p < 0.05
Anemia	12	22.2	16	23.9	0.1	NS
COPD	7	12.96	16	23.9	0.66	NS
Ischaemic etiology	46	85.2	40	59.7	2.72	p < 0.01
Myocardial infarction	23	42.6	9	13.4	1.9	p < 0.05
Segment kinetic disturbances	45	83.3	17	25.3	4.87	p < 0.001
With event	36	66.7	18	26.9	3.05	p < 0.001
Non-survivals	13	24.1	5	7.5	0.99	NS
Rehospitalized within 6 months after discharge	29	53.7	8	11.9	2.84	p < 0.01
With at least 2 hospitalizations for 1 year	33	61.1	13	19.4	3.01	p < 0.01

Table 2. Comparison of main quantitative characteristics according to systolic function.

Characteristics	HFRSF /n=54/	HFPSF /n=67/	Comparison	
			Criterion	p value
Age /mean ± SD/	62.5 ± 7.6	64.1 ± 8.4	F = 1.09	NS /0.3/
EF /%/	28.96 ± 7.7	53.9 ± 7.6	F = 319.5	< 0.0001 /NA/
NTproBNP /median value/	249.839	124.935	Kruskal-Wallis test = 21.6	< 0.0001
TNF-6 /median value/	3.1681	3.5542	Kruskal-Wallis test = 0.23	NS /0.63/
Haemoglobin /g/l/	135 ± 20.1	130 ± 18.0	F = 1.59	NS /0.2/
Creatinine /mg/l/	103 ± 17.8	97 ± 19.9	F = 3.55	NS /0.06/
Sodium /mmol/l/	141 ± 4.2	142 ± 4.0	F = 0.6	NS /0.43/
Potassium /mmol/l/	4.8 ± 0.78	4.75 ± 0.71	F = 0.25	NS /0.62/

Table 3. Subdivision of patients with HFRSF according to the plasma concentration of NTproBNP.

NTproBNP /pg/ml/	Number of patients	Frequency /%/	Cumulative frequency
≤ 100	5	9.3	5
101-300	27	50.0	32
≥ 301	22	40.7	54

Table 4. Subdivision of patients with HFPSF according to the plasma concentration of NTproBNP.

NTproBNP /pg/ml/	Number of patients	Frequency /%/	Cumulative frequency
≤ 100	19	28.4	19
101-300	40	59.7	59
≥ 301	8	11.9	67

Table 5. Comparison between different HRV indices in the event-free and event groups in HFRSF.

HRV index	Event-free/n=7/	With event/n=15/	Comparison	
			Criterion	p value
SDNN /ms/, median	91.0	63.0	Kruskall-Walis test = 3.63	P < 0.05
SDANN /ms/, median	131.0	80.0	Kruskall-Walis test = 5.92	P < 0.05
SDNNindex, median	51.0	27.0	Kruskall-Walis test = 5.1	P < 0.05
SDSD /ms/, median	32.0	29.0	Kruskall-Walis test = 1.8	NS
pNN50 /%/ , median	6.0	3.0	Kruskall-Walis test = 2.03	NS
HRVti, median	28.0	14.0	Kruskall-Walis test = 5.44	P < 0.05
TINN /ms/, median	432.0	225.0	Kruskall-Walis test = 5.25	P < 0.05
rMSSD /ms/, median	32.0	29.0	Kruskall-Walis test = 1.7	NS
LF, median	246.5	143.3	Kruskall-Walis test = 0.55	NS
HF, median	237.4	169.4	Kruskall-Walis test = 0.32	NS
LF/HF, median	1.0	0.9	Kruskall-Walis test = 0.56	NS
Total power, median	1542.0	610.0	Kruskall-Walis test = 1.39	NS




Figure 1. Comparison between the NTproBNP median value in the event-free /1/ and event group /2/ in HFRSF.




Figure 2. Comparison between the NTproBNP median value in the event-free /1/ and event group /2/ in HFPSF.




Figure 3. NTproBNP in patients with HFRSF: Kaplan-Meier event-free survival curves.




Figure 4. NTproBNP in patients with HFPSF: Kaplan-Meier event-free survival curves.




Figure 5. HRV in patients with HFRSF: Kaplan-Meier event-free survival curves.

Acknowledgements:

This study was conducted with the financial help of fund „Scientific research” of the Ministry of Education and Science of Bulgaria.

REFERENCES:

1. Cowie MR, Mosterd A, Wood DA, Deckers JW, Poole-Wilson PA, Sutton GC, et al. The epidemiology of heart failure. *Eur Heart J*. 1997 Feb;18(2):208-225. [PubMed]
2. Braunwald E. Heart Failure. In: Braunwald et al. Harrison's principles of internal medicine. 15th ed. New York, McGraw-Hill, 2001:1318-1331.
3. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. *Circulation*. 1993 Jul;88(1):107-115. [PubMed] [CrossRef]
4. Abassi Z, Karram T, Ellaham S, Winaver J, Hoffman A. Implications of the natriuretic peptide system in the pathogenesis of heart failure & diagnostic and therapeutic importance. *Pharmacol Ther*. 2004 Jun;102(3):223-241. [PubMed] [CrossRef]
5. Dokainish H, Zoghbi WA, Lakkis NM, Ambriz E, Patel R, Quinones MA, et al. Incremental predictive power of B-type natriuretic peptide and tissue Doppler echocardiography in the prognosis of patients with congestive heart failure. *J Am Coll Cardiol*. 2005 Apr 19;45(8):1223-26. [PubMed] [CrossRef]
6. Logeart D, Thabut G, Jourdain P, Chavelas C, Beyne P, Beauvais F, et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of readmission after decompensated heart failure. *J Am Coll Cardiol*. 2004 Feb 18;43(4):645-41. [PubMed] [CrossRef]
7. Gardner RS, Ozalo F, Murday AY, Robb SD, McDonagh TA. N terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. *Eur Heart J*. 2003 Oct;24(19):1735-43. [PubMed] [CrossRef]
8. Hunt PJ, Richardis AM, Nicholls MG, Yandle TG, Doughty RN, Espiner EA. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-proBNP): a new marker of cardiac impairment. *Clin Endocrinol (Oxf)* 1997 Sep;47(3):287-96. [PubMed]
9. Ambrose TM. A review of the clinical utility of NTproBNP in the diagnosis, prognosis, and therapy monitoring of patients with congestive heart failure. *J Clin Ligand Assay*. 2003; 25:160-6.
10. Richards AM, Doughty R, Nicholls MG, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischaemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. *J Am Coll Cardiol*. 2001; 37(7):1781-7.
11. Brouwer J, van Veldhuisen DJ, Man in 't Veld AJ, Haaksma J, Dijk WA, Visser KR, et al. Prognostic value of heart rate variability during long-term follow-up in patients with mild to moderate heart failure. The Dutch Ibopamine Multicenter Trial Study Group. *J Am Coll Cardiol*. 1996 Nov 1;28(5):1183-1189. [PubMed] [CrossRef]
12. Counihan PJ, Fei L, Bashir Y, Farrell TG, Haywood GA, McKenna WJ. Assessment of heart rate variability in hypertrophic cardiomyopathy. Association with clinical and prognostic features. *Circulation*. 1993 Oct;88(4 Pt 1):1682-1690. [PubMed] [CrossRef]
13. Mortara A, Tavazzi L. Prognostic implications of autonomic nervous system analysis in chronic heart failure: role of heart rate variability and baroreflex sensitivity. *Arch Gerontol Geriatr*. 1996 Nov-Dec;23(3):265-275. [PubMed] [PubMed]
14. Takase B, Kurita A, Noritake M, Uehata A, Maruyama T, Nagayoshi H, et al. Heart rate variability in patients with diabetes mellitus, ischemic heart disease, and congestive heart failure. *J Electrocardiol*. 1992 Apr;25(2):79-88. [PubMed] [CrossRef]
15. Woo MA, Stevenson WG, Moser DK, Trelease RB, Harper RM. Patterns of beat-to-beat heart rate variability in advanced heart failure. *Am J Cardiol*. 1992 Mar;123(3):704-710. [PubMed] [CrossRef]
16. Lombardi F, Makikallio TH, Myerburg RJ, Huikuri HV. Sudden cardiac death: role of heart rate variability to identify patients at risk. *Cardiovascular Research*. 2001 May;50(2):210-217. [PubMed] [CrossRef]
17. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. (Marek Malik, writing chairman.) Heart rate variability standards of measurement, physiological interpretation, and clinical use. *Circulation*. 1996; 93:1043-1065.

Adress for corespondence:

Nadya Stancheva
Clinic of Cardiology and Rheumatology; UMHAT Georgi Stranski
8A Georgi Kochev str., 5800 Pleven, Bulgaria
Tel. +359 64 886 140; +359 887 749 946; Fax: +359 64 886 370
e-mail: nadia_stancheva@abv.bg;